Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway

Neuroscience

Volumn 177, Issue , 2011, Pages 159-169

  Kamiyama, H ^a   Matsumoto, M ^a   Otani, S ^b   Kimura, S I ^a   Shimamura, K I ^a   Ishikawa, S ^a   Yanagawa, Y ^a   Togashi, H ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b CNRS   (France)

Author keywords

D1 receptors; GABA neuron; Ketamine; Medial prefrontal cortex; NMDA receptor antagonist; Synaptic transmission

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BICUCULLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; HALOPERIDOL; KETAMINE; OXIDOPAMINE;

ACOUSTIC REFLEX; ANALGESIC ACTIVITY; ANESTHESIA MECHANISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSATE LEVEL; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; EVOKED RESPONSE; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; LONG TERM DEPRESSION; LOW DRUG DOSE; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; STARTLE REFLEX; SYNAPTIC TRANSMISSION;

ANIMALS; HIPPOCAMPUS; KETAMINE; MALE; NEURAL INHIBITION; NEURAL PATHWAYS; PREFRONTAL CORTEX; PRESYNAPTIC TERMINALS; RATS; RATS, WISTAR;

EID: 79952005934     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.12.012     Document Type: Article

References (57)

1. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., Nagren K., Vilkman H., Gustafsson L.L., Syvalahti E., Hietala J. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 2005, 182:375-383.
2. Bandler R., Carrive P., Zhang S.P. Integration of somatic and autonomic reactions within the midbrain periaqueductal grey: viscerotopic, somatotopic and functional organization. Prog Brain Res 1991, 87:269-305.
3. Blot K., Kimura S., Kemp A., Manahan-Vaughan D., Giros B., Otani S. The effect of non-competitive NMDA receptor antagonist MK801 on hippocampus-prefrontal cortex synaptic responses and executive cognitive function in rats. 2nd Biennial Schizophrenia International Research Conference Florence, Italy 2010.
4. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 1990, 47:181-188.
5. Chizh B.A. Low dose ketaine: a therapeutic and research tool to explore N-methyl-d-aspartate (NMDA), receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007, 21:259-271.
6. Cilia J., Hatcher P., Reavill C., Jones D.N. (±) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 2007, 21:302-311.
7. Fejgin K., Safonov S., Palsson E., Wass C., Engel J.A., Svensson L., Klamer D. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 2007, 191:377-385.
8. Fell M.J., Katner J.S., Johnson B.G., Khilevich A., Schkeryantz J.M., Perry K.W., Svensson K.A. Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge. Neuropharmacology 2010, 58:632-639.
9. Goto Y., Otani S. Prefrontal cortical synaptic plasticity: the roles of dopamine and implication for schizophrenia. Monoaminergic modulation of cortical excitability 2007, 165-174. Springer, New York, NY. K.Y. Tseng, M. Atzori (Eds.).
10. Harrison P.J., Owen M.J. Genes for schizophrenia?. Recent findings and their pathophysiological implications. Lancet 2003, 361:417-419.
11. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003, 23:6315-6326.
12. A receptors containing α6 and δ subunits. J Neurosci 2008, 28:5383-5393.
13. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 24:11496-11500.
14. Hunt M.J., Kassal K., Garcia R. Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats. J Neurosci 2005, 25:524-531.
15. A receptor agonistic properties of ketamine: compulsive and anesthetic behavioral models in mice. Anesth Analg 2000, 91:230-236.
16. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004, 101:8467-8472.
17. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 2007, 78:69-108.
18. Jay T.M., Burette F., Laroche S. NMDA receptor-dependent long-term potentiation in the hippocampal afferent fiber system to the prefrontal cortex in the rat. Eur J Neurosci 1995, 7:247-250.
19. Jodo E., Suzuki Y., Katayama T., Hoshino K.Y., Takeuchi S., Niwa S., Kayama Y. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb Cortex 2005, 15:663-669.
20. Judo C., Matsumoto M., Yamazaki D., Hiraide S., Yanagawa Y., Kimura S., Shimamura K., Togashi H. Early stress exposure impairs synaptic potentiation in the rat medial prefrontal cortex underlying contextual fear extinction. Neuroscience 2010, 169:1705-1714.
21. 2 receptors: implications for models of schizophrenia. Mol Psychiatry 2002, 7:837-844.
22. Kikuchi T., Wang Y., Shinbori H., Sato K., Okumura F. Effects of ketamine and pentobarbitone on acetylcholine release from the rat frontal cortex in vivo. Br J Anaesth 1997, 79:128-130.
23. Klepstad P., Maurset A., Moberg E.R., Oye I. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 1990, 187:513-518.
24. Konradi C., Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2005, 97:153-179.
25. Koseki H., Matsumoto M., Togashi H., Miura Y., Fukushima K., Yoshioka M. Alteration of synaptic transmission in the hippocampal-mPFC pathway during extinction trials of context-dependent fear memory in juvenile rat stress models. Synapse 2009, 63:805-813.
26. Kubota T., Hirota K., Yoshida H., Takahashi S., Anzawa N., Ohkawa H., Kushikata T., Matsuki A. Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats. Psychopharmacology (Berl) 1999, 146:335-338.
27. Lewis D.A., Cho R.Y., Carter C.S., Eklund K., Forster S., Kelly M.A., Montrose D. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 2008, 165:1585-1593. [erratum: 166:120].
28. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6:312-324.
29. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006, 63:1372-1376.
30. Lindefors N., Barati S., Oconnor W.T. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 1999, 759:205-212.
31. Lorrain D.s., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
32. Ma J., Leung L.S. The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology (Berl) 2007, 191:961-974.
33. Maione S., Marabese I., Rossi F., Berrino L., Palazzo E., Trabace L. Effects of persistent nociception on periaqueductal gray glycine release. Neuroscience 2000, 97:311-316.
34. Mandillo S., Rinaldi A., Oliverio A., Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 2003, 14:533-544.
35. Matsumoto M., Shikanai H., Togashi H., Izumi T., Kitta T., Hirata R., Yamaguchi T., Yoshioka M. Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats. Brain Res 2008, 1195:50-55.
36. Matsumoto M., Togashi H., Ohashi S., Tachibana K., Yamaguchi T., Yoshioka M. Serotonergic modulation of psychological stress-induced alteration in synaptic plasticity in the rat hippocampal CA1 field. Brain Res 2004, 1022:221-225.
37. Matsuura N., Shibukawa Y., Kato M., Ichinohe T., Suzuki T., Kaeko Y. Ketamine, not fentanyl, suppresses pain-related magnetic fields associated with trigemially innervated area following CO2 laser stimulation. Neurosci Res 2008, 62:105-111.
38. Morgan C.J., Mofeez A., Brandner B., Bromley L., Curran H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004, 29:208-218.
39. Morris B.J., Cochrans S.M., Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005, 5:101-106.
40. Nakao S., Adachi T., Murakawa M., Shinomura T., Kurata J., Shichino T., Shibata M., Tocyama I., Kimura H., Mori K. Halothane and diazepam inhibit ketamine-induced c-fos expression in the rat cingulate cortex. Anesthesiology 1996, 85:874-882.
41. Nelson C.L., Burk J.A., Bruno J.P., Sarter M. Effects of acute and repeated systemic administration of ketamine on prefrontal acetylcholine release and sustained attention performance in rats. Psychopharmacology (Berl) 2002, 161:168-179.
42. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
43. Oye I., Paulsen O., Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-d-aspartate receptors. J Pharmacol Exp Ther 1992, 260:1209-1213.
44. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, New York, NY. 2nd ed.
45. Pratt W.E., Mizumori S.J. Neurons in rat medial prefrontal cortex show anticipatory rate changes to predictable differential rewards in a spatial memory task. Behav Brain Res 2001, 123:165-183.
46. 2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2009, 19:849-860.
47. Seamans J.K., Gorelova N., Durstewitz D., Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001, 21:3628-3638.
48. Seillier A., Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 2009, 204:410-415.
49. Sultan F., Glickstein M. The cerebellum: comparative and animal studies. Cerebellum 2007, 6:168-176.
50. Suzuki Y., Jodo E., Takeuchi S., Niwa S., Kayama Y. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 2002, 114:769-779.
51. Swerdlow N.R., Bakshi V., Walkar M., Taaid N., Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 1998, 140:75-80.
52. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001, 156:194-215.
53. Takahata R., Moghaddam B. Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 2003, 28:1117-1124.
54. Thach W.T. On the mechanism of cerebellar contributions to cognition. Cerebellum 2007, 6:163-167.
55. 1-like dopamine receptor activation modulates GABAergic inhibition but not electrical coupling between neocortical fast-spiking interneurons. J Neurosci 2008, 28:2633-2641.
56. Volk D.W., Lewis D.A. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 2002, 77:501-505.
57. 1 dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 2001, 11:452-462.